Investment Update: Zydus Lifesciences Secures USFDA Approval for Generic Ascorbic Acid Injection

Regulatory Milestone & Exclusivity Opportunity Zydus Lifesciences has received final USFDA approval to market its generic equivalent of Ascor® (Ascorbic Acid Injection USP, 25,000 mg/50 mL and 5,000 mg/10 mL). Crucially, the US regulator has designated this Abbreviated New Drug Application (ANDA) as a Competitive Generic Therapy (CGT). This strategic designation qualifies the product for a potential 180-day marketing exclusivity period, which commences upon the first day of commercial launch. The reference drug currently commands a US market size of approximately $11.6 million annually, according to IQVIA data for the 12 months ending June 2026. Operational Execution & Pipeline Depth The injection will be manufactured at Zydus’s approved injectable facility in Jarod, Gujarat, and distributed by its US subsidiary, Zydus Pharmaceuticals (USA) Inc. This approval strengthens the firm's impressive regulatory track record, taking its total USFDA approvals to 448 against 513 cumulative ANDAs filed as of June 30, 2026. The consistent rollout of niche injectables reinforces management's strategic focus on capturing value in low-competition generic segments in the US. Financial Context & Market Performance This positive regulatory tailwind arrives on the heels of the company's Q1 results. Zydus demonstrated robust top-line growth, with quarterly revenue expanding 22% year-over-year to ₹8,017 crore. However, profitability faced near-term headwinds; consolidated net profit contracted 36% YoY to ₹939.8 crore, and EBITDA margins compressed to 24.1% from 31.8%. Despite margin moderation, underlying market sentiment remains constructive. The stock maintains a strong year-to-date appreciation of 20.76%, currently trading near the ₹1,104 level.